Home >Current Issue

Volume: 9, Issue: 2, February, 2019
DOI: 10.7324/JAPS.2019.90204



Research Article

A validated LC-MS/MS method for the pharmacokinetic study of alogliptin in healthy rabbits

Yatha Ravi1, Bigala B. Rajkamall, 2

  Author Affiliations


Abstract

A liquid chromatography-tandem mass spectrophotometric (LC-MS/MS) method was developed for quantification of Alogliptin in rabbit plasma employing Liquid-Liquid extraction technique. The developed method was validated for specificity, precision, accuracy, recovery, and stability characteristics. Chromatographic separation was achieved on Inertsil ODS 5 µm C18, 50 × 4.60 mm with 30:70 v/v of 0.1% formic acids: Organic Mixture (acetonitrile: methanol, 80:20% v/v) as an isocratic mobile phase with a flow rate of 1.0 ml/min. the developed LC-MS method was applied to assess pharmacokinetics parameters of alogliptin tablet in healthy rabbits. Alogliptin showed Tmax of 2.6 ± 0.37 h and mean Cmax, AUC 0-t and AUC0 for test formulation is 90.6 ± 4.41, 1675.41 ± 164 and 3726.47 ± 796 respectively.

Keywords:

Alogliptin, Pharmacokinetics, LC-MS/ MS, Diabetes mellitus.



Citation: Ravi Y, Rajkamal BB. A validated LC-MS/MS method for the pharmacokinetic study of alogliptin in healthy rabbits. J App Pharm Sci, 2019; 9(2): 29-37.


Copyright: The Author(s). This is an open access article distributed under the Creative Commons Attribution Non-Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shawet JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103(2):137-149. https://doi.org/10.1016/j.diabres.2013.11.002

Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 2008;51(5):703-713. https://doi.org/10.1007/s00125-008-0936-9

Kaneto H, Katakami N, Matsuhisa M, Taka-aki M. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediat Inflamm 2010;2010:1-12. https://doi.org/10.1155/2010/453892

Robertson RP, Harmon J, Tran POT. B-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53:119-24. https://doi.org/10.2337/diabetes.53.2007.S119

Drucker DJ. Glucagon-like peptides. Diabetes.1998;47:159-169. https://doi.org/10.2337/diab.47.2.159

Nauck MA. Is glucagon-like peptide-1 an incretin hormone? Diabetologia 1999;42(3):373-379. https://doi.org/10.1007/s001250051165

Wang Y, Egan JM, Raygada M. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 1995;136:4910-4917. https://doi.org/10.1210/endo.136.11.7588224

Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995;136(8):3585-3596. https://doi.org/10.1210/endo.136.8.7628397

Deacon CF, Nauck MA, Toft-Nielsen M. Both subcutaneously and intravenously administered glucagonlike peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44(9):1126-1131. https://doi.org/10.2337/diab.44.9.1126

Moritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., Odaka, H. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur. J. Pharmacol. 2009;602:448–54. https://doi.org/10.1016/j.ejphar.2008.11.017

Yadav J, Kadam V, Mohite K, J. Curr. Pharma Res. 2014; 4:1286–1290.

Sharma K and Parle A. Int. Bull. Drug Res. 2015; 5: 81–89.

El-Bagary R, I Elkady E, F Ayoub BM. Int. J. Biomed. Sci. 2012; 8:215–218.

Zhang K, Ma P, Jing W, Zhang X. Asian J. Pharm. Sci. 2015;10:152–158.

Deng J, Guo J, Dai R, Zhang G, Xie H. J. Pharm. Biomed. Anal. 2015;117:99–103. https://doi.org/10.1016/j.jpba.2015.08.033

Yadav J, Jadhav S, Mohite K, Int. J. Pharm. Pharm. Res. 2014;1:1–9.

ICH guidelines for the stability of new drug substances and products. Q1A(R2) ICH, Geneva; 2005. p. 1-13.

ICH guidelines for validation of analytical procedures: text and methodology. Q2(R1) ICH, Geneva; 2005. p. 1-14.

Article Metrics